Articles tagged "Renal function"

2015 American Transplant Congress
Impact of Proton Pomp Inhibitors on Hypomagnesemia and Arterial Stiffness in Renal Transplant Recipients
S. Sezer,¹ B. Gurlek Demirci,¹ M. Erkmen Uyar,¹ S. Uyanik,² M. Haberal.³
¹Department of Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey; ²Department of Intrenal Medicine, Baskent University Faculty of Medicine, Ankara, Turkey; ³Department of General Surgery, Baskent University Faculty of Medicine, Ankara, Turkey.
Purpose: Hypomagnesemia predicts cardiovascular morbidity and mortality in the general population and accelerated loss of kidney function in renal transplant recipients (RTRs). Proton pomp inhibitors…
2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
W. Arns,¹ K. Budde,¹ C. Sommerer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ P. Reinke,¹ I. Hauser,¹ R. Stahl,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ V. Kliem.¹
¹Herakles Study Group, Germany; ²Novartis, Pharma, Germany; ³Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…
2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
T. Horwedel,¹ L. Bowman,¹ W. Chapman,² J. Hagopian.¹
¹Barnes-Jewish Hospital, St. Louis, MO; ²Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…
2015 American Transplant Congress
A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan
S.-M. Wang,¹ P.-C. Lee,² J.-D. Lian,³ K.-H. Shu,⁴ S.-T. Wu,⁵ H.-C. Chen,⁶ C.-C. Huang,⁷ M.-S. Wu,⁸ Y.-C. Tian,⁹ Y.-J. Chiang,¹⁰ Y.-T. Chen,¹¹ H.-P. Wang.¹²
¹National Taiwan University Hospital, Taipei, Taiwan; ²National Cheng Kung University Hospital, Tainan, Taiwan; ³Chung Shan Medical University Hospital, Taichung, Taiwan; ⁴Taichung Veteran's General Hospital, Taichung, Taiwan; ⁵TriService General Hospital, Taipei, Taiwan; ⁶Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; ⁷China Medical University Hospital, Taichung, Taiwan; ⁸Taipei Medical University Hospital, Taipei, Taiwan; ⁹ChangGung Memorial Hospital–Taipei, Taipei, Taiwan; ¹⁰ChangGung Memorial Hospital–LinKou, Taoyuan, Taiwan; ¹¹ChangGung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan; ¹²E-Da Hospital, Kaohsiung, Taiwan.
The study aimed to assess the clinical safety and tolerability of everolimus (EVR) in Taiwan kidney transplant patients.This study enrolled 203 kidney transplant recipients, between…
2015 American Transplant Congress
Improved Renal Function Post-Liver Transplant With Earlier Everolimus Conversion
S. Lin,¹ M. Zimmerman,² V. Lewis,¹ S. Biggins,³ C. Ruller,⁴ I. Kam,⁴ T. Nydam.⁴
¹Pharmacy Dept, University of Colorado Hospital, Aurora; ²Division of Transplant Surgery, Medical College of Wisconsin, Wisconsin; ³Division of Gastroenterology/Hepatology, University of Colorado, Aurora; ⁴Division of Transplant Surgery, University of Colorado, Aurora.
Calcineurin inhibitors (CNI) play an important role in preventing acute rejection (AR) post-liver transplant. Its long-term use is limited by development of nephrotoxicity. Optimal timing…
2015 American Transplant Congress
Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
F. Lehner,¹ K. Budde,¹ R. Wuethrich,² P. Reinke,¹ W. Arns,¹ A. Muehlfeld,¹ U. Eisenberger,¹ R. Stahl,¹ K. Heller,¹ O. Witzke,¹ B. Suwelack,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,³ C. Sommerer.¹
¹ZEUS Study Group, Germany; ²ZEUS Study Group, Switzerland; ³Novartis, Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living donation subgroup of kidney de novo transplant recipients after conversion to an…